Latest filing published 04 Nov 2021 for Alimera Sciences INC, €37k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
James R. Largent: trading record in brief
This profile gathers the share dealings of James R. Largent across 2 companies, led by Biolase, Inc and Alimera Sciences Inc. Between 12 May 2008 and 3 November 2021, the trades on record add up to 6 filings.
On the market, this insider has only ever bought: 6 purchases, €70k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. In 2021 alone, the filings show 1 purchase and no sales.
The median purchase comes to €8,308.
The latest filing, published on 4 November 2021, reports an open-market purchase of €37k in Alimera Sciences Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to James R. Largent
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 10,000 shares@ US$4.309100.0% of flowCommon StockSEC:0001474506-21-000159:0Canonical exit: 1 Feb 2022 (T+90)
- 3,000 shares@ US$5.1127.1% of flowCommon StockSEC:0001267602-19-000194:0Canonical exit: 17 Feb 2020 (T+90)
- 4,900 shares@ US$2.93Common StockSEC:0001209191-08-029862:0Canonical exit: 10 Aug 2008 (T+90)
- 1,200 shares@ US$2.94Common StockSEC:0001209191-08-029862:1Canonical exit: 10 Aug 2008 (T+90)
- 3,851 shares@ US$2.95Common StockSEC:0001209191-08-029862:2Canonical exit: 10 Aug 2008 (T+90)
- 49 shares@ US$2.96Common StockSEC:0001209191-08-029862:3Canonical exit: 10 Aug 2008 (T+90)
6 of 6 declarations
